KEVIN ROA: Open Payments
NPI 1609597392 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,411 in 148 payments from 15 companies in 2025. Trend: 2023 $808 · 2024 $1,754 · 2025 $3,411
Food & beverage: $3,301Education: $109
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 33 | $741 |
| Neurocrine BioSciences, Inc. | 19 | $503 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $368 |
| Alkermes, Inc. | 13 | $356 |
| E.R. Squibb & Sons, L.L.C. | 21 | $339 |
| Teva Pharmaceuticals USA, Inc. | 9 | $258 |
| Vanda Pharmaceuticals Inc. | 8 | $246 |
| ABBVIE INC. | 7 | $220 |
| Janssen Pharmaceuticals, Inc | 5 | $108 |
| Axsome Therapeutics, Inc. | 3 | $66 |
Products named: REXULTI, INGREZZA, CAPLYTA, ARISTADA, COBENFY, FANAPT, VRAYLAR, ABILIFY MAINTENA.
Industry payments across NV — which companies pay providers there.
